S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in

Ampio Pharmaceuticals Stock Forecast, Price & News

-0.22 (-13.33 %)
(As of 03/3/2021 12:00 AM ET)
Today's Range
Now: $1.43
50-Day Range
MA: $1.77
52-Week Range
Now: $1.43
Volume3.30 million shs
Average Volume4.58 million shs
Market Capitalization$264.63 million
P/E RatioN/A
Dividend YieldN/A
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado.
Ampio Pharmaceuticals logo


Ampio Pharmaceuticals, Inc. to Host Earnings Call
March 3, 2021 |  finance.yahoo.com
AMPE Jul 2021 2.500 call
February 7, 2021 |  uk.finance.yahoo.com
AMPE Jul 2021 0.500 call
February 7, 2021 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$0.04 per share


Net Income$-13,630,000.00


Market Cap$264.63 million
Next Earnings Date5/4/2021 (Estimated)


Overall MarketRank

1.33 out of 5 stars

Medical Sector

694th out of 1,968 stocks

Pharmaceutical Preparations Industry

343rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.22 (-13.33 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMPE News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions

Is Ampio Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ampio Pharmaceuticals stock.
View analyst ratings for Ampio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ampio Pharmaceuticals?

Wall Street analysts have given Ampio Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ampio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ampio Pharmaceuticals' next earnings date?

Ampio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Ampio Pharmaceuticals

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) posted its quarterly earnings results on Wednesday, May, 6th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04).
View Ampio Pharmaceuticals' earnings history

How has Ampio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ampio Pharmaceuticals' stock was trading at $0.5307 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMPE stock has increased by 169.5% and is now trading at $1.43.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AMPE?

1 equities research analysts have issued 1-year price objectives for Ampio Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ampio Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 179.7% from the stock's current price.
View analysts' price targets for Ampio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the following people:
  • Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 69, Pay $305k)
  • Mr. Daniel G. Stokely CPA, CPA, CFO, Corp. Sec. & Treasurer (Age 57, Pay $276k)
  • Ms. Holli Cherevka, Chief Operating Officer (Age 38, Pay $278k)
  • Lane Hapke, VP of Manufacturing Operations
  • April Ramirez, Clinical Trial Mang.
  • Laura Goldberg, VP of Quality and Regulatory Operations

Who are some of Ampio Pharmaceuticals' key competitors?

What other stocks do shareholders of Ampio Pharmaceuticals own?

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

Who are Ampio Pharmaceuticals' major shareholders?

Ampio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.68%), Willis Investment Counsel (0.66%), Brighton Jones LLC (0.22%), Northern Trust Corp (0.17%), Cypress Capital Management LLC WY (0.12%) and Strategic Financial Services Inc (0.10%).
View institutional ownership trends for Ampio Pharmaceuticals

Which institutional investors are selling Ampio Pharmaceuticals stock?

AMPE stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Cypress Capital Management LLC WY, LPL Financial LLC, Raymond James Financial Services Advisors Inc., and Traynor Capital Management Inc..
View insider buying and selling activity for Ampio Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Ampio Pharmaceuticals stock?

AMPE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Willis Investment Counsel, ExodusPoint Capital Management LP, Jane Street Group LLC, Bank of New York Mellon Corp, Captrust Financial Advisors, Brighton Jones LLC, and Cutter & CO Brokerage Inc..
View insider buying and selling activity for Ampio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $1.43.

How much money does Ampio Pharmaceuticals make?

Ampio Pharmaceuticals has a market capitalization of $264.63 million. The specialty pharmaceutical company earns $-13,630,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does Ampio Pharmaceuticals have?

Ampio Pharmaceuticals employs 23 workers across the globe.

What is Ampio Pharmaceuticals' official website?

The official website for Ampio Pharmaceuticals is ampiopharma.com.

Where are Ampio Pharmaceuticals' headquarters?

Ampio Pharmaceuticals is headquartered at 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500.

This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.